Featured Research

from universities, journals, and other organizations

Tracking drug's ability to prevent type 1 diabetes

Date:
September 16, 2013
Source:
Vanderbilt University Medical Center
Summary:
Researchers will examine the ability of the drug abatacept to prevent type 1 diabetes (T1D), observing the effects of the drug in people at high risk to develop T1D.

Vanderbilt's Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

T1D, formerly called juvenile diabetes, is an autoimmune disease that is predominant in the younger population and has a strong genetic component. The study is seeking participants between the ages of 6 and 45 whose antibody screening results indicate they have a strong likelihood of developing T1D.

"People often think that screening for type 1 diabetes risk factors is unimportant because there is currently nothing that can be done to mitigate their risk level for type 1 diabetes," said William Russell, M.D., Cornelius Vanderbilt Professor of Pediatrics, director of Pediatric Endocrinology and Diabetes at Monroe Carell Jr. Children's Hospital at Vanderbilt and protocol chair for the international trial.

"The ultimate goal of this trial is to find a method to prevent, or at least delay, the development of type 1 diabetes in persons most at risk," Russell said.

Abatacept, under the brand name Orencia, is FDA approved for the treatment of the autoimmune disease rheumatoid arthritis. Abatacept has shown success in interrupting autoimmune attacks on the body's insulin-producing cells in people newly-diagnosed with T1D.

"The autoimmune process that leads to type 1 diabetes can begin long before any symptoms appear," Russell said. "Autoantibodies that target the insulin-producing cells in the pancreas can be present months or even years before a person develops diabetes. Although the presence of these autoantibodies does not signify certainty of developing type 1 diabetes, it can be a very strong indicator and an opportunity to identify people at risk."

Having a blood relative with T1D is why the first participant, Ric Hudgins, joined the trial.

Hudgins says he made a concerted effort to learn all he could about the disease after his 10-year-old son was diagnosed, leading him to become involved with TrialNet and subsequently the abatacept trial.

"I wanted to learn all I could about the disease and I wanted to help in any way to progress potential treatments or preventions for the disease," Hudgins said.

"Although this study is targeted toward people who have a high risk of developing type 1 diabetes, and therefore cannot help my son, hopefully trials like these can help researchers find ways to prevent other children from receiving a type 1 diabetes diagnosis."

Hudgins said that his son, now almost 13, is managing his disease very well and is proud that his family is involved in research trials like this one.

The process of enrolling in T1D prevention trials begins with an antibody screening of a blood relative of someone with T1D, at no cost through the National Institutes of Health-funded TrialNet Pathway to Prevention Study (5U01DK085465-05).

Participants in the prevention trial will receive 14 intravenous infusions of abatacept over a one-year period, returning every six months for tests to determine the efficacy of the drug in limiting immune system damage to the healthy insulin-producing cells.

"This trial focuses on prevention and widening the spectrum of what we can do for people at risk of developing diabetes," Russell said.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Vanderbilt University Medical Center. "Tracking drug's ability to prevent type 1 diabetes." ScienceDaily. ScienceDaily, 16 September 2013. <www.sciencedaily.com/releases/2013/09/130916110825.htm>.
Vanderbilt University Medical Center. (2013, September 16). Tracking drug's ability to prevent type 1 diabetes. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2013/09/130916110825.htm
Vanderbilt University Medical Center. "Tracking drug's ability to prevent type 1 diabetes." ScienceDaily. www.sciencedaily.com/releases/2013/09/130916110825.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins